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Introduction 19
Type 1 diabetes (T1D) is an autoimmune condition marked by loss of glycemic control 20 caused by immune-mediated destruction of insulin producing beta cells that reside within the 21 pancreatic islets of Langerhans (1) . Replacement of lost beta cells by adult islet allogeneic 22 transplantation restores glycemic control, providing fine-tuned release of insulin in response 23 to blood glucose in real-time, something not yet achievable by manual or automatic injection 24 of insulin or its analogues (2) (3) (4) . Islet transplantation reduces exogenous insulin requirements 25 and reverses hypo-glycemic unawareness, a life-threatening complication of T1D (3, 5, 6) . 26 Although highly successful, the need for robust suppression of host immunity to avoid 27 rejection precludes its indication for pediatric T1D patients, restricting the broader 28 application of islet transplantation to adults with life threatening hypoglycemic unawareness 29 (2, 7) . 30 Islet transplantation is further restricted by the scarcity and fragility of islets. Frequently 31 patients require multiple islet infusions extracted from multiple pancreata to achieve clinical 32 outcomes of insulin independence and reversal of hypo-glycemic unawareness (4, 6, 8) . 33 Further to this, most islet transplant recipients show relatively poor long-term outcomes 34 compared to solid organ transplant recipients, requiring a return to insulin injections within a 35 few years post-islet transplant (2, 4) . Evidence suggests the underlying mechanisms leading 36 to reduced islet allograft survival are unique to islet transplantation and include recurrent islet 37 autoimmunity, sensitivity of islets to the intra-portal transplant site and islet-toxicity of 38 immunosuppressive drugs, as well as factors present in solid organ transplantation such as 39 chronic allograft rejection (2) . These factors are likely exacerbated by autologous islet 40 inflammation induced via the isolation process and ex vivo culture that may hasten graft 41 failure and increase their immunogenicity after transplant (9) (10) (11) . Strategies that reduce islet 42 fragility and inflammation could preserve islet graft-mass and improve post-transplant 43 function potentially reducing the reliance on heavy immunosuppression and widening the 44 eligibility criteria for an islet transplant (10) . 45 TNFAIP3, encoding the ubiquitin editing protein A20, is a master regulator of NF-κB 46 signalling. A20 through its ovarian tumor (OTU) and zinc finger 4 domain modifies ubiquitin 47 chains on key intracellular inflammatory signalling mediators, primarily RIP1 and TRAF6 48 (12, 13) that lie downstream of inflammatory and danger sensing receptors of the TNF 49 receptor family, including TNFR1, IL-1R and TLRs. In hematopoietic cells A20 functions as 50 a negative regulator of immuno-stimulatory factors and thus governs the threshold for 51 immune activation. Reduced expression of A20 in dendritic cells leads to increased 52 expression of costimulatory molecules and an enhanced ability to activate CD8 + and CD4 + T 53 cells during an immune response (14) (15) (16) . Further, deletion of A20 in B cells, macrophages 54 and granulocytes results in cell intrinsic hyper-activation and spontaneous inflammatory 55 disease in mice (17) (18) (19) (20) . In human subjects A20 haploinsufficiency is associated with 56 increased serum cytokines, higher frequencies of TH17 cells and autoimmune disease (21, 57 22) . Thus, by regulating NF-κB activation, A20 sets the threshold for the generation of a 58 productive immune response. Here we investigated the impact of changed A20 expression 59 levels in islet allografts on immune-stimulatory thresholds and islet allograft survival. 60
Results 61

Forced expression of A20 allows permanent islet allograft survival without needing 62 immunosuppression 63
To test the impact of A20 on tissue tolerance, we transduced primary islets with an adenoviral 64 vector (rAd.A20) to force A20 expression to high levels ( Figure 1A and Supplemental Figure  65 1), which resulted in a robust suppression of the normal pro-inflammatory gene response 66 following TNF and IL1β stimulation ( Figure 1 , B and C). Further analysis in beta cell lines 67 showed that increasing A20 levels suppressed TNF-induced NF-kB and JNK signalling 68 pathways, inhibited activation of a NF-kB and a AP-1 reporter, and suppressed expression of 69 pro-inflammatory factors associated with allograft rejection (Supplemental Figure 2 ) (9) . 70
Next, primary islets from BALB/c (H2 d ) donor mice transduced with rAd.A20 were 71 transplanted into diabetic C57Bl/6 (H2 b ) allogeneic recipients. Adenoviral transduction did 72 not affect islet graft function in vivo as demonstrated by the ability of both rAd.A20, control 73 rAd.GFP (GFP-expressing) and non-infected (NI) grafts to rapidly restore euglycemia 74 following transplantation ( Figure 1D ). Kaplan-meier survival analysis showed rapid rejection 75 of control NI and rAd.GFP transduced islet grafts allografts ( Figure 1E ). In contrast, ~ half of 76 mice receiving A20 expressing islets failed to reject their grafts and instead exhibited 77 permanent (>200 days) allograft survival. Graft removal by survival nephrectomy for some 78 recipients at post-operative day (POD) 100 disrupted glucose control, illustrating that A20-79 transduced surviving islet grafts were both functional and responsible for euglycemia ( Figure  80 1F). Long-term surviving A20-transduced grafts were characterised by normal islet 81 architecture, robust insulin production and distinct pockets of mononuclear cells within the 82 graft microenvironment ( Figure 1G ). Enhanced graft morphology was also evident for A20-83 expressing grafts at POD 10 ( Figure 1H ). Thus, forced expression of A20 allows permanent 84 and functional survival of an islet allograft without needing immunosuppressive drugs. 85
Immune features of A20-induced islet allograft survival 86
We investigated the immunological mechanism for long-term survival of A20-expressing 87 allografts. After 150 days post transplantation, splenic T cells were harvested from mice with 88 A20-expressing BALB/c (H2 d ) islet grafts and were adoptively transferred to RAG -/mice 89 previously transplanted with a BALB/c (H2 d ) islet allograft. Control groups received splenic 90 T cells harvested from C57/BL6 mice (Figure 2A ). In this situation the majority of RAG -/-91 mice receiving T cells taken from mice with surviving A20-expressing grafts took longer to 92 reject their islet grafts, and the majority permanently accepted the allograft, compared to 93 RAG-/-mice receiving T cells from naïve C57/BL6 mice ( Figure 2B ). Thus, A20-induced 94 islet allograft acceptance is T cell dependent. To determine whether graft acceptance was due 95 to T cell anergy, deletion or regulation, we repeated the above experiment but this time only 96 transferred FACS-purified CD4+ CD25-effector T cells from mice harbouring long-term 97 surviving A20-expressing or control non-infected islet grafts. These T cell preparations 98 lacked CD4+ CD25+ T cells with regulatory potential (23, 24) . In this experiment all of the 99 recipient mice rejected the second BALB/c allograft regardless of whether they received 100 effector T cells from mice with A20-expressing grafts or control grafts ( Figure 2B ). This 101 indicated to us that A20-expression engendered T cell dependent tolerance. To test if graft 102 acceptance was specific to the BALB/c (H2 d ) alloantigen, we established another cohort of 103 long-term surviving A20-expressing islet graft recipient mice to repeat the above experiment. 104
However, in this case the T cells from mice harbouring A20-expressing long-term surviving 105 grafts were adoptively transferred into RAG -/mice pre-transplanted with a MHC-disparate 106 graft from a different (H2 k ) donor strain ( Figure 2C ). Subsequently, in all cases the H2 k 107 MHC-mismatched grafts were rapidly rejected. We conclude from these experiments that 108 A20-expression does not delete effector T cells or impair their function, or induce T cell 109 anergy, but rather results in T cell dependent and antigen specific immune regulation towards 110 an islet allograft. 111 112
Forced expression of A20 engenders Foxp3 + T cells 113
Both A20-and GFP-expressing islet allografts were infiltrated with FOXP3 + cells at POD 10 114 after transplantation ( Figure 3A The increased number of Foxp3 + cells in A20-expressing grafts was associated with reduced 125 levels of pro-inflammatory mRNA in the graft site at POD10 that associate with islet graft 126 rejection (9, 25) as compared to expression levels observed for GFP-expressing grafts ( Figure  127 3F). These same mRNAs were also suppressed in long-term surviving A20-expressing grafts 128 ( Figure 3F ). Further to these data we found a noticeable reduction in the frequency of CD8 + 129 and CD4 + positive cells within the A20-expressing grafts ( Figure 3E ). However, A20 130 expressing grafts exhibited elevated levels of Tgfβ and a trend to increased levels of Il10 and 131 also no overall change in the level of dendritic cell activation markers Cd80 or Cd86 between 134 A20-or GFP-expressing grafts at POD 10 (Figure 3 , F). Within long-term surviving grafts 135 (>100 days) FOXP3 + cells and high levels of Foxp3 mRNA was readily detected (Figure 3 , C 136 and F). Therefore A20 alters the pro-inflammatory millieu and engenders regulatory T cells 137 within the graft microenvironment. 138
To further investigate the role of regulatory T cells in A20-induced tolerance we treated 139 diabetic recipient mice with the αCD25 mAb PC61, which depletes CD25 + FOXP3 + 140 regulatory T cells (27) (Supplemental Figure 3 ), by preventing CD25 binding to interleukin 2 141 (28, 29) . In this experiment, all of the mice receiving A20-transduced grafts and treated with 142 PC61 mAb rapidly rejected their grafts with similar rejection times to those observed for 143 control GFP-expressing grafts ( Figure 3G ). In contrast, 40% of recipients of A20 expressing 144 grafts injected with an isotype control antibody exhibited long-term survival ( Figure 3G ). We 145 conclude that graft intrinsic expression of A20 can promote regulatory T cell dependent 146 tolerance to an MHC mismatched islet allograft. 147
Rapamycin (also known as sirolimus) inhibits mammalian target of rapamycin (mTOR) and 148 is used clinically as an immunosuppressant to dampen T cell responses in transplantation (4, 149 6) . Preclinical and clinical studies also indicate that rapamycin promotes FOXP3 + regulatory 150 T cells (30-33), therefore we investigated whether graft intrinsic expression of A20 would 151 synergise with the tolerance promoting properties of rapamycin. For the experiment diabetic 152 C57BL/6 recipients received A20-expressing H-2 d BALB/c islet allografts, as well as seven 153 daily injections of a limiting subtherapeutic dose of rapamycin (25) starting on the day of 154 transplantation ( Figure 3H ). All control GFP-expressing grafts, and those treated with 155 rapamycin alone, were rapidly rejected, whereas mice receiving A20-expressing grafts and 156 treated with a subtherapeutic dose of rapamycin showed superior graft survival compared to 157 grafts transduced with A20 alone ( Figure 3H ). These latter data highlight the translational 158 potential of A20 to synergise with clinical approaches to promote significant improvements 159 in islet allograft outcomes. 160 161 A20 promotes tissue tolerance by regulating RIPK1 162
As increasing intra-graft A20 levels can promote allograft tolerance by increasing the 163 threshold for NF-kB activation we investigated whether A20 reduction would have the 164 reverse effect and promote inflammation with more aggressive allograft rejection. To test this 165 we utilised an ENU-mutagenesis generated mouse line harbouring a germline A20 loss of 166 function mutation (34) . This coding mutation lies within A20's functional OTU ubiquitin 167 editing domain (12) and substitutes a conserved isoleucine at amino acid position 325 for an 168 asparagine (I325N). When transiently expressed in pancreatic beta cell lines the I325N 169 mutation cripples A20's ability to inhibit TNF-induced NF-kB and JNK reporter activation 170 ( Figure 4A -C), and when overexpressed in wild-type mouse islets the I325N A20 variant 171 shows a reduced ability to inhibit TNF-induced inflammatory gene expression as compared to 172 islet expressing wild-type A20 ( Figure 4D ). A20 regulates inflammatory signalling by 173 terminating RIPK1 activation via cleavage of K63 ubiquitin chains with its OTU domain and 174 targeting substrates for K48-mediated proteosomal degradation via its zinc finger 4 ubiquitin 175 ligase domain (12) . The I325N mutation does not alter A20 protein stability, nor A20's 176 capacity to interact with key substrates RIP1K1 or NEMO in beta cells (Supplemental Figure  177   4 ). Rather, the I325N mutation resulted in increased accumulation of hyper-polyubiquitinated 178 isoforms of RIPK1 (Supplemental Figure 4A ) and increased RIPK1 levels in TNF simulated 179 cells (Supplemental Figure 4 , A and C), consistent with a reduction in A20's ubiquitin editing 180 function (12) . Further to this, islets isolated from I325N mice exhibited increased TNF-181 induced proinflammatory signalling and gene expression compared to wild type islets ( Figure  182 4, E and F). When transplanted into diabetic allogeneic recipients I325N islets showed 183 accelerated rejection, and a hyper-inflammatory graft microenvironment with reduced 184 expression of factors associated with immune regulation including tgfb, l10 and ctla4 ( Figure  185 4G-I). Thus, A20 is necessary to control islet homeostasis in response to inflammatory 186 triggers. In the specific context of islet transplantation changing A20 levels can function as an 187 immune modulatory control switch that dictates transplant outcomes. 188 189 Forced expression of A20 improves the metabolic function of neonatal porcine islets 190 post transplantation 191
In the clinical scenario adult human islets are transplanted into patients with T1D and 192 hypoglycemic unawareness (5) . The supply of suitable organ donors limits clinical islet 193 transplantation and neonatal porcine islets (NPI) may be able to bridge that gap (35) (36) (37) (38) . We 194 tested whether the protective and anti-inflammatory properties of A20 would transfer to NPI 195 and thus demonstrate the potential for clinical translation. We transduced NPI with rAd.A20 196 to achieve high levels of A20 expression without evidence of toxicity, which blunted TNF- tissue factor (TF) ( Figure 5D ), which plays a critical role in triggering posttransplant 200 coagulation and enhances islet graft loss (39, 40) . To test the beneficial efficacy of A20 in 201 vivo, rAd.A20 transduced NPI were transplanted under the renal capsule of diabetic RAG -/-202 mice and the time to normalisation of blood glucose was followed. A20-expressing NPI 203 provided superior blood glucose control illustrated by a more rapid normalisation of 204 posttransplant blood glucose and a normalised glucose tolerance (ipGTT) compared to mice 205 receiving control NPI grafts ( Figure 5 , E and F). 206
Discussion 208
Here we investigated the impact of changing A20 expression levels in islet allografts on 209 immune-stimulatory thresholds and islet allograft survival. A potential role for A20 in 210 transplantation was first indicated in a rodent heart xenotransplantation model where it was 211 found that surviving hearts showed intra-graft A20 expression compared to rejecting hearts 212 (41) . Further studies showed that A20 reduces endothelial inflammation during 213 xenotransplantation (42) , the severity of graft arteriosclerosis (43) and improves liver graft 214 function (44) . Regarding pancreatic islets and beta cells, A20 expression is transcriptionally 215 regulated in beta cells by NF-κB (45) but also involved in negative regulation of NF-κB 216 activation (46) . This suggests that manipulating A20 levels in islets would have a good safety 217 profile but also have clinical potential as an approach for the suppression of otherwise 218 deleterious NF-κB-dependent inflammatory genes (10). This is supported by studies showing 219 A20 to be a potent inhibitor of NF-κB-mediated inflammation and cell death in pancreatic 220 islets (47) (48) (49) , and improving metabolic control of islets in a syngeneic transplant model 221 when overexpressed (50) . Here we demonstrate for the first time that islet-A20 dictates islet 222 allograft fate. A20 overexpression engenders the accumulation of intra-graft antigen-specific 223
regulatory T-cells that provide local tissue tolerance and islet graft survival. In contrast loss 224 of A20 function accelerates rejection. 225
Our data fits with accumulating evidence in various tissues that show TNFAIP3 to be a 226 crucial gene for the maintenance of tolerance via its role in dampening responses to NF-κB-227 inducing inflammatory mediators. Indeed, A20 expression increases the threshold for 228 immune cell activation, and reducing A20 in dendritic cells (14-16), T cells (51), B cells (17, 229 18) , macrophages and granulocytes (19) , results in their autosomal activation, with improved 230 antigen presenting activity in the case of A20-deficient dendritic cells and spontaneous 231 inflammatory disease in mice. In addition, A20 plays a central role to maintain intestinal 232 tolerance, where a loss of A20 leads to aberrant responses to gut microbiota with intestinal 233 inflammation (20, 52) . The requirement of A20 for tissue homeostasis is highlighted by the 234 fact that the A20 locus has been associated with many autoimmune and inflammatory 235 disorders by GWAS (53) . Further to this, A20 haploinsufficient human subjects present with 236 increased TH17 cells and inflammatory disease (21, 22) , whereas mice with A20 germline 237 deficiency succumb to uncontrolled inflammation (54) . 238
Here we show that manipulating A20 levels to achieve tissue tolerance can be directed to 239 improve islet transplantation outcomes. Future studies will focus on generating clinical grade 240 vectors for the delivery of A20. The continued maturation of gene delivery technology and 241 gene editing techniques in pig tissues (55) provides additional opportunities for tissue 242 engineering with A20. Our findings also indicate that the strategy of increasing A20 243 expression in the graft will synergise with other clinically tested as well as emerging graft 244 tolerance-inducing approaches. These would include rapamycin and abatacept (4, 6, 56) , as 245 well as islet expression of the regulatory T cell attractant CCL22 (57), or graft expression of 246 CTLA4-Ig that prevents T-cell activation (58) , and local expression of the anti-inflammatory 247 agent alpha-1-antitrypsin (59) . 
Neonatal porcine islet isolation 282
Donor pancreases were surgically removed from either sex neonatal piglets and islets isolated 283 as previously described (60) . 
Recombinant adenovirus mediated gene transfer 314
Islets and insulinoma MIN6 cells were transduced with recombinant adenovirus (rAd.) to 315 over-express GFP (rAd.GFP) or A20 (rAd.A20) as described previously (47, 49) . The rAD-316 GFP construct was a kind gift from Beth Israel Harvard Medical School, Boston, MA, USA. 317
The rAd vector expressing A20 was a gift from Dr. V. Dixit (Genentech, Inc., CA, USA). For 318 islet gene transduction, islets were inoculated with virus at the stated multiplicity of infection, 319 and incubated for 1.5 h at 37°C in 0.5 ml serum free RPMI-1640 medium (Gibco). Islets were 320 then ready for further culture or transplantation. MIN6 cells were plated at a density of 321 ~1x106/well in 6-well tissue culture plates (Corning CoStar) and inoculated with virus at the 322 optimal MOI of 100:1 in DMEM (Gibco). After 1.5 h, cells were replenished with DMEM 323 10% FCS and cultured a further 24 h before use. Adenovirus was propagated by infecting 324 HEK293 cells in six T175 vented flasks (Coring CoStar). Cells were lysed and adenoviruses 325 were extracted using Aenopure kit according to instructions provided (PureSyn Inc.). The 326 purified virus was titrated and quantified in HEK293 cells using the Adeno-X Rapid Titer Kit 327 IκBα protein expression, primary islets or MIN6 cells were cultured for 24 h after gene 335 transduction and lysed in RIPA buffer, ~10 µg of total protein was resolved on a 10% SDS 336 PAGE gel and then transferred to a nitrocellulose membrane. Membranes were incubated 337 with polyclonal anti-A20 (Abcam, UK) and IκBα (Cell Signalling Technology, USA) 338 respectively, and followed by peroxidase labelled secondary antibodies. Signals were 339 visualised using an ECL detection kit (Amersham Pharmacia Biotech, Australia). 340 341
Reporter Assays 342
Reporter assays were carried out essentially as we have described (45, 66) . plasmids and reporters were obtained and maintained as described previously (45, 66) . Systems). In some experiments cells were also pre-treated with pharmacological inhibitors, 391 pyrrolidine dithiocarbamate (PDTC) and SP600125 (Sigma-Aldrich). Inhibitors were added 392 at listed concentrations and incubated with cells at 37 o C for 1.5 h prior to cytokine 393 stimulation or islet transplantation. Total RNA was extracted using the RNeasy Plus Mini Kit 394 (Qiagen) and reverse transcribed using Quantitect Reverse Transcription Kit (Qiagen). 395
Primers were designed using Primer3 (67) with sequences obtained from GenBank and 396 synthesized by Sigma Aldrich (Supplemental Table 1 and 2). PCR reactions were performed 397 on the LightCycler® 480 Real Time PCR System (Roche) using the FastStart SYBR Green 398
Master Mix (Roche). Cyclophilin (CPH2) and ACTB were used as housekeeping genes and 399 data analysed using the 2ΔΔCT method. Initial denaturation was =performed at 95° C for 10 400 sec, followed by a three-step cycle consisting of 95° C for 15 sec =(4.8° C/s, denaturation), 401 63° C for 30 sec (2.5° C/sec, annealing), and 72° C for 30 sec (4.8° C/s, elongation). A melt-402 curve was performed after finalization of 45 cycles at 95° C for 2 min, 40° C for 3 min and 403 gradual increase to 95° C with 25 acquisitions/° C. 404 405
Flowcytometry: 406
Flow cytometry Flow cytometric staining was performed as described (27) . Data were 407 acquired with CytoFLEX (Beckman) or CantoII (BD) flow cytometer and analysed using 408 strategy and (B) Kaplan-Meier survival data of RAG -/mice pretransplanted with a BALB/c graft and adoptively transferred with T cells or CD25 depleted T effector cells, from mice harbouring long-term surviving grafts (A20 T cells, n = 9; A20 T effector cells., n = 3) or control C57BL/6 mice (B6 T cells, n = 5; B6 T effector cells n = 5). (C) Kaplan-Meier survival data of RAG -/mice pre-transplanted with a third-party CBA (H2 k ) graft and adoptively transferred with T cells or CD25 depleted T effector cells from mice harbouring long-term surviving grafts (A20 T cell, n = 4; A20 T effector cell., n = 2) or control C57BL/6 mice (Bl6 T cell, n = 4; B6 T effector cell, n = 2). Log rank test used for significance **P<0.01. 
